CERS
Price
$1.24
Change
-$0.05 (-3.88%)
Updated
Aug 7 closing price
Capitalization
342.62M
83 days until earnings call
STXS
Price
$2.20
Change
-$0.05 (-2.22%)
Updated
Aug 7, 04:59 PM (EDT)
Capitalization
214.36M
Earnings call today
Interact to see
Advertisement

CERS vs STXS

Header iconCERS vs STXS Comparison
Open Charts CERS vs STXSBanner chart's image
Cerus
Price$1.24
Change-$0.05 (-3.88%)
Volume$1.14M
Capitalization342.62M
Stereotaxis
Price$2.20
Change-$0.05 (-2.22%)
Volume$585
Capitalization214.36M
CERS vs STXS Comparison Chart in %
Loading...
CERS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
STXS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
CERS vs. STXS commentary
Aug 08, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CERS is a StrongBuy and STXS is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Aug 08, 2025
Stock price -- (CERS: $1.24 vs. STXS: $2.19)
Brand notoriety: CERS and STXS are both not notable
Both companies represent the Medical Specialties industry
Current volume relative to the 65-day Moving Average: CERS: 103% vs. STXS: 68%
Market capitalization -- CERS: $342.62M vs. STXS: $214.36M
CERS [@Medical Specialties] is valued at $342.62M. STXS’s [@Medical Specialties] market capitalization is $214.36M. The market cap for tickers in the [@Medical Specialties] industry ranges from $3.82T to $0. The average market capitalization across the [@Medical Specialties] industry is $8.69B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CERS’s FA Score shows that 0 FA rating(s) are green whileSTXS’s FA Score has 0 green FA rating(s).

  • CERS’s FA Score: 0 green, 5 red.
  • STXS’s FA Score: 0 green, 5 red.
According to our system of comparison, CERS is a better buy in the long-term than STXS.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CERS’s TA Score shows that 2 TA indicator(s) are bullish while STXS’s TA Score has 3 bullish TA indicator(s).

  • CERS’s TA Score: 2 bullish, 6 bearish.
  • STXS’s TA Score: 3 bullish, 6 bearish.
According to our system of comparison, STXS is a better buy in the short-term than CERS.

Price Growth

CERS (@Medical Specialties) experienced а -3.12% price change this week, while STXS (@Medical Specialties) price change was -3.52% for the same time period.

The average weekly price growth across all stocks in the @Medical Specialties industry was +0.63%. For the same industry, the average monthly price growth was -1.59%, and the average quarterly price growth was -3.41%.

Reported Earning Dates

CERS is expected to report earnings on Oct 30, 2025.

STXS is expected to report earnings on Nov 06, 2025.

Industries' Descriptions

@Medical Specialties (+0.63% weekly)

Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
CERS($343M) has a higher market cap than STXS($214M). STXS YTD gains are higher at: -1.316 vs. CERS (-19.481). STXS has higher annual earnings (EBITDA): -21.24M vs. CERS (-26.34M). CERS has more cash in the bank: 65.9M vs. STXS (19.8M). STXS has less debt than CERS: STXS (5.49M) vs CERS (96M). CERS has higher revenues than STXS: CERS (156M) vs STXS (26.8M).
CERSSTXSCERS / STXS
Capitalization343M214M160%
EBITDA-26.34M-21.24M124%
Gain YTD-19.481-1.3161,481%
P/E RatioN/AN/A-
Revenue156M26.8M582%
Total Cash65.9M19.8M333%
Total Debt96M5.49M1,749%
FUNDAMENTALS RATINGS
CERS vs STXS: Fundamental Ratings
CERS
STXS
OUTLOOK RATING
1..100
6383
VALUATION
overvalued / fair valued / undervalued
1..100
43
Fair valued
92
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
97100
PRICE GROWTH RATING
1..100
8451
P/E GROWTH RATING
1..100
10061
SEASONALITY SCORE
1..100
9050

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

CERS's Valuation (43) in the Medical Specialties industry is somewhat better than the same rating for STXS (92). This means that CERS’s stock grew somewhat faster than STXS’s over the last 12 months.

CERS's Profit vs Risk Rating (100) in the Medical Specialties industry is in the same range as STXS (100). This means that CERS’s stock grew similarly to STXS’s over the last 12 months.

CERS's SMR Rating (97) in the Medical Specialties industry is in the same range as STXS (100). This means that CERS’s stock grew similarly to STXS’s over the last 12 months.

STXS's Price Growth Rating (51) in the Medical Specialties industry is somewhat better than the same rating for CERS (84). This means that STXS’s stock grew somewhat faster than CERS’s over the last 12 months.

STXS's P/E Growth Rating (61) in the Medical Specialties industry is somewhat better than the same rating for CERS (100). This means that STXS’s stock grew somewhat faster than CERS’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
CERSSTXS
RSI
ODDS (%)
N/A
Bearish Trend 2 days ago
78%
Stochastic
ODDS (%)
Bullish Trend 1 day ago
85%
Bullish Trend 2 days ago
83%
Momentum
ODDS (%)
Bearish Trend 1 day ago
81%
Bearish Trend 2 days ago
80%
MACD
ODDS (%)
Bearish Trend 1 day ago
82%
Bearish Trend 2 days ago
90%
TrendWeek
ODDS (%)
Bearish Trend 1 day ago
85%
Bearish Trend 2 days ago
84%
TrendMonth
ODDS (%)
Bearish Trend 1 day ago
82%
Bullish Trend 2 days ago
82%
Advances
ODDS (%)
Bullish Trend 16 days ago
76%
Bullish Trend 25 days ago
77%
Declines
ODDS (%)
Bearish Trend 7 days ago
84%
Bearish Trend 7 days ago
81%
BollingerBands
ODDS (%)
N/A
Bearish Trend 2 days ago
82%
Aroon
ODDS (%)
Bearish Trend 1 day ago
86%
Bullish Trend 2 days ago
79%
View a ticker or compare two or three
Interact to see
Advertisement
CERS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
STXS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
CAJFF28.32N/A
N/A
Canon, Inc.
CMOPF75.00N/A
N/A
Cosmo Pharmaceuticals NV
UVRBF1.50N/A
N/A
Universal Robina
DIGTF0.02N/A
N/A
Thruvision Group PLC
PRTT0.65N/A
N/A
Protect Pharmaceutical Corp

CERS and

Correlation & Price change

A.I.dvisor indicates that over the last year, CERS has been loosely correlated with LAB. These tickers have moved in lockstep 52% of the time. This A.I.-generated data suggests there is some statistical probability that if CERS jumps, then LAB could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CERS
1D Price
Change %
CERS100%
-3.88%
LAB - CERS
52%
Loosely correlated
+0.78%
NNOX - CERS
48%
Loosely correlated
-1.70%
ITGR - CERS
46%
Loosely correlated
+0.34%
CLPT - CERS
46%
Loosely correlated
+1.20%
ICUI - CERS
46%
Loosely correlated
+2.62%
More

STXS and

Correlation & Price change

A.I.dvisor indicates that over the last year, STXS has been loosely correlated with SMTI. These tickers have moved in lockstep 40% of the time. This A.I.-generated data suggests there is some statistical probability that if STXS jumps, then SMTI could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To STXS
1D Price
Change %
STXS100%
+0.45%
SMTI - STXS
40%
Loosely correlated
+0.12%
TWST - STXS
36%
Loosely correlated
-5.89%
CERS - STXS
35%
Loosely correlated
+0.78%
ICUI - STXS
35%
Loosely correlated
-1.65%
RGEN - STXS
33%
Poorly correlated
-3.26%
More